ReviewFrontiers in oncology2026
Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a major cause of cancer-related mortality worldwide, largely due to late diagnosis and pronounced molecular heterogeneity. Although genomic and transcriptomic studies have advanced understanding of gastric tumor biology, they do not fully capture dynamic changes in protein expression, post-translational modifications, and signaling activity that directly regulate cellular function. High-throughput proteomic technologies, particularly protein microarrays, have emerged as powerful platforms for systematic protein profiling in complex biological samples. These technologies enable the simultaneous quantification of hundreds to thousands of proteins with high sensitivity and minimal sample requirements, supporting both discovery and translational research. Recent applications of protein microarrays in gastric cancer include biomarker discovery for early diagnosis, molecular subtyping, characterization of the tumor microenvironment, and assessment of therapeutic response. Multi-protein biomarker panels and integration with computational approaches have demonstrated improved diagnostic performance compared with conventional single-marker assays. In addition, proteomic profiling has provided insights into key signaling pathways and immune-related mechanisms underlying tumor progression and drug resistance. This review summarizes the principles and major formats of protein microarray technologies and highlights their applications in gastric cancer. Current challenges and future directions for clinical translation are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.